AYTU BIOPHARMA, INC (AYTU)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Jun 30
In fiscal 2025, AYTU BIOPHARMA, INC reported revenue of $66.38M, up 1.8% from the prior year. The company ran a net loss, with a net margin of -20.4% and a gross margin of 69.0%.
Key ratios (FY2025)
69.0%
Gross margin
-11.8%
Operating margin
-20.4%
Net margin
-71.5%
Return on equity
+1.8%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $66.38M | $65.18M | $107.40M | $96.67M | $65.63M | $27.63M | — | — | — | — |
| Cost of Revenue | $20.55M | $16.13M | $40.77M | $44.39M | — | — | — | — | — | — |
| Gross Profit | $45.83M | $49.05M | $66.63M | $52.28M | $29.20M | $19.35M | — | — | — | — |
| Operating Income | -$7.83M | -$1.59M | -$17.07M | -$109.91M | -$58.87M | -$21.13M | -$16.85M | -$19.70M | -$20.13M | -$21.70M |
| Net Income | -$13.56M | -$15.84M | -$17.05M | -$108.78M | -$58.29M | -$13.62M | -$27.13M | -$10.19M | -$22.51M | -$28.18M |
| EPS (Diluted) | $-2.16 | $-2.86 | $-5.11 | $-74.01 | $-3.48 | — | — | — | — | — |
| Total Assets | $124.18M | $118.09M | $136.46M | $137.62M | $265.67M | $153.29M | $34.72M | $21.06M | $15.00M | $24.34M |
| Total Liabilities | — | — | $97.11M | $93.31M | $128.10M | $58.28M | $27.63M | $7.64M | $11.00M | $14.26M |
| Shareholders' Equity | $18.97M | $27.72M | $39.36M | $44.31M | $137.57M | $95.02M | $7.09M | $13.42M | $4.00M | $10.09M |
| Cash & Equivalents | $30.95M | $20.01M | $22.98M | $19.36M | $49.65M | $48.08M | $11.04M | $7.01M | $802.3K | $8.05M |
| Operating Cash Flow | -$1.94M | -$1.39M | -$5.13M | -$28.82M | -$25.96M | -$28.37M | -$13.83M | -$15.94M | -$13.83M | — |
| Capital Expenditures | $228.0K | $329.0K | — | — | — | $0 | $59.8K | $74.7K | $111.6K | $252.9K |
| Shares Outstanding | 8.98M | 5.97M | 5.52M | 1.93M | 27.49M | 12.58M | 17.54M | 1.79M | 41.2K | 187.1K |